Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Samarth Kulkarni, Chief Executive Officer of CRISPR Therapeutics AG (NASDAQ:CRSP), sold 4,242 shares of the company’s common stock at $66.60 on October 14, 2025, for a total of $282517.
On October 13, Kulkarni also exercised options to acquire 8,334 common shares. These shares were related to the vesting of restricted stock units. With a market capitalization of $6.56 billion, CRISPR Therapeutics is approaching its next earnings announcement on October 29, 2025. InvestingPro subscribers have access to 15+ additional exclusive insights about CRSP’s financial health and growth prospects.
Following these transactions, Kulkarni directly owns 205,096 shares of CRISPR Therapeutics AG. Kulkarni also indirectly owns 85,662 shares through The Kulkarni 2023 GRAT. Despite recent volatility, the stock has demonstrated strong momentum, posting an impressive 84.39% return over the past six months.
In other recent news, CRISPR Therapeutics has filed a prospectus with the U.S. Securities and Exchange Commission to offer up to $600 million in new common shares. The shares will be sold through Jefferies LLC under an existing Open Market Sale Agreement, allowing the company to sell shares at its discretion. Additionally, CRISPR Therapeutics reported promising preclinical data for its alpha-1 antitrypsin deficiency therapy candidate, CTX460, which showed significant efficacy in disease models. Citizens has reiterated a Market Outperform rating with an $86.00 price target for CRISPR Therapeutics, highlighting the potential of the company’s SyNTase Editor technology. BMO Capital also reiterated an Outperform rating with a $75.00 price target, noting the company’s partnership with Sirius on FXI siRNA SRSD107 and the initiation of a Phase II trial in venous thromboembolism prevention. Furthermore, H.C. Wainwright has maintained a Buy rating with an $80.00 price target, emphasizing the potential of SRSD107 in the anticoagulation market. These developments reflect ongoing interest and activity in CRISPR Therapeutics’ research and financial strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.